A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma
Study of Milademetan in Comparison to Trabectedin in Patients with Liposarcoma
Sponsor: Rain Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT8161
U.S. Govt. ID: NCT04979442
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn about the safety, tolerability, and effectiveness of an investigational drug called milademetan as compared to the use of trabectedin. In this study, subjects will be randomly assigned (like flipping a coin) to receive one of two study drugs: milademetan or trabectedin. This is an open-label study, meaning you will know which study drug you are assigned to receive. The total duration of study participation will vary by subject and is not known in advance. If you join this study, you could take part in a Screening Period, several 28-day (for milademetan) or 21-day (for trabectedin) treatment cycles, an End of Treatment Visit, and several follow-up visits after you stop treatment.
Investigator
Gary Schwartz, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with liposarcoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162